Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies

Fulvestrant-3-boronic acid (ZB716), an oral selective estrogen receptor degrader (SERD) under clinical development, has been investigated in ADME studies to characterize its absorption, metabolism, and pharmacokinetics. ZB716 was found to have high plasma protein binding in human and animal plasma,...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiawang, Rajasekaran, Nirmal, Hossain, Ahamed, Zhang, Changde, Guo, Shanchun, Kang, Borui, Jung, Hunsoon, Kim, Hongjoong, Wang, Guangdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400955/
https://www.ncbi.nlm.nih.gov/pubmed/34451816
http://dx.doi.org/10.3390/ph14080719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400955/
https://www.ncbi.nlm.nih.gov/pubmed/34451816
http://dx.doi.org/10.3390/ph14080719

Ejemplares similares